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OBJECTIVE — The relationship between circulating markers of inﬂammation and arterial
stiffness in children with type 1 diabetes is not well studied. We tested whether inﬂammatory
monocyte chemoattractant protein (MCP)-1 concentrations correlate with arterial stiffness or
type 1 diabetes status.
RESEARCH DESIGN AND METHODS — MCP-1 concentrations and radial tonometry
data were available for 98 children with type 1 diabetes and 55 healthy control subjects. Arterial
stiffnesswascalculatedasaugmentationindexcorrectedforaheartrateof75(AI75).Correlation
between MCP-1 and AI75 and differences in MCP-1 concentrations between case and control
subjects were tested.
RESULTS — MCP-1 was signiﬁcantly higher in children with type 1 diabetes than in control
subjects (P  0.001). However, there were no correlations between MCP-1 and AI75 in the
overall sample or upon stratiﬁcation by type 1 diabetes status (range P  0.28–0.66).
CONCLUSIONS — Circulating MCP-1 was not associated with arterial stiffness but was
signiﬁcantly elevated in children with type 1 diabetes, indicating a proinﬂammatory state in
children as young as 10 years. The clinical signiﬁcance of MCP-1 elevation in type 1 diabetes
needs further investigation.
Diabetes Care 32:465–467, 2009
T
ype 1 diabetes is associated with en-
dothelial inﬂammation and arterial
stiffness. We previously demon-
strated that arterial stiffness is apparent in
type 1 diabetic children as young as 10
years when compared with matched con-
trol subjects (1) but noted poor correla-
tion with both traditional cardiovascular
disease (CVD) risk factors (A1C, LDL
cholesterol, and family history) and novel
serumCVDriskfactors(interleukin-6,tu-
mor necrosis factor, C-reactive protein,
superoxide dismutase, and nitric oxide)
(1,2). Notably, a genetic association with
arterial stiffness was seen (3). We postu-
lated that the lack of correlation between
arterial stiffness and previously studied
risk factors was likely representative of
the low short-term absolute risk for mac-
rovascular events in our young type 1 di-
abetic cohort. Given that the majority of
CVD events in type 1 diabetic patients are
clustered among those with concurrent
diabeticnephropathy,wesoughttodeter-
mine if monocyte chemoattractant pro-
tein (MCP)-1, a serum marker with
known correlation to CVD events and di-
abetic nephropathy, would correlate with
arterial stiffness in children with type 1
diabetes (4). As MCP-1 is stimulated by
chronic hyperglycemia and is responsible
for induction of superoxide anion, cyto-
kine production, and adhesion molecule
expression (5), exploration of potential
correlation with global vascular dysfunc-
tion in children with type 1 diabetes was
warranted.
In this analysis, we sought to deter-
minewhetherMCP-1concentrationscor-
relate with arterial stiffness as measured
by radial artery tonometry and to validate
previous associations between circulating
MCP-1 concentrations and type 1 diabe-
tes status in a case-control analysis.
RESEARCH DESIGN AND
METHODS— The study population
and method for arterial stiffness measure-
ment have been previously described (1).
Brieﬂy, children with type 1 diabetes of at
least 1-year duration were recruited from
the Florida Diabetes Camp. Control chil-
dren were recruited from general pediat-
rics practices in Gainesville, Florida.
Eligible children had no CVD and no his-
tory of antihypertensive or lipid-lowering
medication use. Blood was collected, and
augmentation index corrected for a heart
rate of 75 (AI75) was measured by radial
tonometry in children who fasted for at
least8ha spreviously described (1). Se-
rumlipidsandcytokines,bloodA1C,and
plasma glucose were analyzed as previ-
ously reported (1). Serum MCP-1 con-
centrationswerequantiﬁedbycytometric
ﬂuorescence detection (R&D Systems,
Minneapolis, MN) and natural log (ln)-
transformed before analyses. The study
was approved by the institutional review
board of the University of Florida, and
children were enrolled after written con-
sent and assent.
RESULTS— AI75 measurements and
MCP-1 concentrations were available for
98 children with type 1 diabetes and 55
healthy control subjects (Table 1). Both
groups were well matched for age, heart
rate, and total and LDL cholesterol. Con-
trol subjects had signiﬁcantly higher BMI
and triglycerides and lower HDL choles-
terol. LnMCP-1 correlated with triglycer-
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otherlipidparametersincontrolortype1
diabetic subjects.
Overall in the study population (N 
153), there was no correlation between
lnMCP-1 concentrations and AI75 (r 
0.04; P  0.66). Furthermore, there were
no signiﬁcant correlations between ln-
MCP-1 concentrations and AI75 when
childrenwerestratiﬁedbytype1diabetes
status: type 1 diabetes r  0.11, P 
0.28;childrenwithouttype1diabetesr
0.12, P  0.38. AI75 did not differ
across tertiles of lnMCP-1 in both chil-
dren with and without type 1 diabetes.
Among those with type 1 diabetes, AI75
values across lnMCP-1 tertiles were
6.38  9.47, 1.89  10.19, and 4.59 
12.45 (P  0.20; P for trend  0.32).
Among children without type 1 diabetes,
AI75 values across lnMCP-1 tertiles were
0.14  5.91, 4.42  10.72, and
5.03  11.92 (P  0.26; P for trend 
0.14).
Despite the lack of association be-
tween lnMCP-1 and AI75, lnMCP-1 con-
centrations differed between children
with and without type 1 diabetes. Ln-
MCP-1 concentrations were 5.75  0.39
pg/ml and 5.36  0.45 pg/ml in children
with and without type 1 diabetes, respec-
tively (P  0.001).
CONCLUSIONS — Most studies of
chemokinesinadultswithtype1diabetes
have concentrated on their correlation
with microvascular disease (6–8). How-
ever, studies of chemokines in children
with type 1 diabetes have largely been
performed to examine the potential of
chemokines to predict or explain devel-
oping or ongoing autoimmunity (9). Ele-
vated MCP-1 concentrations have been
previously documented in children with
newly diagnosed type 1 diabetes when
compared with children at increased risk
of developing diabetes and control sub-
jects (10).
In this study, we conﬁrmed that se-
rum MCP-1 concentrations are elevated
in children with type 1 diabetes in com-
parison with matched control subjects.
Nevertheless, MCP-1 levels failed to cor-
relate with noninvasive measures of arte-
rial stiffness, regardless of whether
comparisonsweremadeamongtype1di-
abetic subjects, control subjects, or the
entire study population. Interestingly,
MCP-1 levels in our type 1 diabetic pop-
ulation correlated with triglyceride levels.
The observed correlation between serum
MCP-1andtriglyceridesintype1diabetic
subjects provides support for the concept
of MCP-1 as a marker or a potential me-
diator of CVD in the type 1 diabetic pop-
ulation. As we failed to reject the null
hypothesis, additional analyses were not
performedinordertoavoidstatisticalbias
for this focused study. A larger study de-
signed to control for additional con-
founders (such as sleep apnea) and
powered to evaluate the role of lipids, ad-
ditional chemokines, acute glycemic
changes, albuminuria, age, sex, pubertal
status, duration of diabetes, and longitu-
dinal A1C values would likely yield addi-
tional informative data on the role of
MCP-1 in type 1 diabetes.
Given the strong associations be-
tween MCP-1 and CVD in large adult
populationstudies,elevatedMCP-1levels
likely reﬂect some component of overall
lifetime macrovascular risk in type 1 dia-
betic patients (11). The low absolute risk
of near-term CVD in children with high
long-termriskmayaccountforthelackof
correlation between MCP-1 and arterial
stiffness in this relatively young cohort.
Becausesystemiccytokineconcentrations
may be inﬂuenced by multiple factors not
solely related to arterial stiffness per se,
such as acute stress, time of day, and meta-
bolic status, serum MCP-1 concentrations
at a single time point may imprecisely cor-
relate with the speciﬁc arterial stiffness
phenotype. Rather, MCP-1 concentra-
tions could more plausibly provide a
global index of inﬂammatory burden of
disease, as was seen in the signiﬁcant dif-
ferenceinMCP-1bydiabetesstatusinour
analysis.
In summary, serum MCP-1 levels are
higher in children with type 1 diabetes
thanincontrolsubjectsandcorrelatewith
triglycerides but not with arterial stiff-
ness. Future efforts will be directed to ex-
plore the potential relationship between
triglycerides and MCP-1 as we attempt to
identify sensitive and speciﬁc serum
markerspredictiveoflong-termCVDrisk
in children with type 1 diabetes.
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MCP-1 (pg/ml) 337.9  122.1 234.9  106.8 0.001 — —
LnMCP-1 (pg/ml) 5.75  0.39 5.36  0.45 0.001 — —
Age (years) 12.9  1.4 13.6  2.3 0.084 0.02 (0.84) 0.06 (0.64)
BMI (kg/m
2) 22.0  3.5 24.0  5.4 0.003 0.11 (0.29) 0.10 (0.46)
A1C (%) 8.5  1.2 5.27  0.3 0.001 0.05 (0.60) 0.004 (0.097)
Heart rate (bpm) 78.6  11.8 76.5  11.7 0.22 0.03 (0.77) 0.05 (0.70)
Fasting glucose (mg/dl) 161.8  70.4 85.1  8.8 0.001 0.06 (0.52) 0.10 (0.46)
Total cholesterol (mg/dl) 159.4  32.3 158.7  28.2 0.87 0.11 (0.29) 0.17 (0.22)
LDL cholesterol (mg/dl) 88.1  26.6 88.4  24.5 0.98 0.10 (0.36) 0.15 (0.28)
HDL cholesterol (mg/dl) 57.3  11.3 51.6  11.9 0.003 0.17 (0.1) 0.09 (0.51)
Triglycerides (mg/dl) 68.5  61.2 94.9  59.3 0.008 0.20 (0.04) 0.18 (0.55)
Data are means  SD, P, and rs (P).
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